Rinvoq reviews and complaints frequently concern symptom improvement, side effects, laboratory monitoring, prescription cost, insurance approval, specialty-pharmacy service and access to manufacturer support.
Rinvoq is the brand name for upadacitinib, a prescription Janus kinase inhibitor manufactured by AbbVie. It changes immune-system signaling and is approved for several inflammatory and autoimmune conditions. Rinvoq is not a dietary supplement or an over-the-counter product.
Patient experiences can differ substantially according to the condition being treated, dosage, age, previous treatment, other medications and individual health risks. A review describing one person’s response cannot establish whether Rinvoq is appropriate or safe for someone else.
Important FDA Boxed WarningRinvoq carries an FDA boxed warning concerning serious infections, mortality, malignancies, major adverse cardiovascular events and thrombosis.
Patients should read the current Medication Guide and discuss the benefits and risks with their prescribing healthcare professional. Do not begin, stop or change Rinvoq based solely on an online review.
Rinvoq Review SummaryPositive Rinvoq reviews often describe reduced pain, inflammation, stiffness, itching or gastrointestinal symptoms, depending on the condition. Some patients also appreciate that Rinvoq is available as an oral medication.
Negative reviews may describe limited or temporary effectiveness, infections, acne, headaches, fatigue, weight changes, laboratory abnormalities, other suspected side effects, high out-of-pocket costs or delays involving insurance and specialty pharmacies.
- Potential Benefits Reported: Symptom relief, improved daily function, oral administration and response after previous treatments were unsuccessful
- Potential Concerns: Serious safety warnings, infections, other side effects, required monitoring, prior authorization and cost
- Zero Stars Rating Status: No reviews had been published when this article was updated. A displayed 0 therefore represents no rating history, not a neutral patient rating.
Rinvoq and AbbVie Contact Information
- Brand Name: Rinvoq
- Generic Name: Upadacitinib
- Manufacturer: AbbVie Inc.
- Drug Class: Janus kinase inhibitor
- Manufacturer Address: 1 North Waukegan Road, North Chicago, IL 60064
- RINVOQ Complete Patient Support: 1-800-274-6867
- AbbVie Medical Information: 1-844-663-3742
- AbbVie Side-Effect and Product-Quality Reporting: 1-800-633-9110
- FDA MedWatch: 1-800-332-1088
- Official Website: Rinvoq.com
- Full Prescribing Information: Rinvoq prescribing information
- FDA Medication Label: DailyMed Rinvoq label
Patient-support representatives can assist with program, insurance and access questions but do not replace the prescribing healthcare professional. Medical decisions and treatment-related questions should be directed to the patient’s healthcare team.
Is Rinvoq FDA Approved?
Yes. Rinvoq was initially approved in the United States in 2019. The current prescribing information includes treatment indications across nine disease areas.
- Rheumatoid Arthritis: Adults with moderately to severely active disease after an inadequate response or intolerance to one or more tumor necrosis factor blockers
- Psoriatic Arthritis: Adults and children age 2 or older with active disease after an inadequate response or intolerance to one or more TNF blockers
- Atopic Dermatitis: Adults and children age 12 or older with refractory moderate to severe disease that is not adequately controlled by other systemic treatments or when those treatments are inadvisable
- Ulcerative Colitis: Adults with moderately to severely active disease who meet the treatment-history requirements in the prescribing information
- Crohn’s Disease: Adults with moderately to severely active disease who meet the treatment-history requirements in the prescribing information
- Ankylosing Spondylitis: Adults with active disease after an inadequate response or intolerance to one or more TNF blockers
- Non-Radiographic Axial Spondyloarthritis: Adults with active disease and objective signs of inflammation after an inadequate response or intolerance to TNF-blocker therapy
- Polyarticular Juvenile Idiopathic Arthritis: Patients age 2 or older with active disease after an inadequate response or intolerance to one or more TNF blockers
- Giant Cell Arteritis: Adults with giant cell arteritis
Approval for a condition does not mean the medication is appropriate for every patient with that diagnosis. Several indications have specific age, disease-severity and previous-treatment requirements.
How Rinvoq Is Taken
Rinvoq extended-release tablets are taken by mouth with or without food. The tablets should be swallowed whole and should not be split, crushed or chewed.
Rinvoq LQ is an oral solution used for certain pediatric patients. The oral solution and extended-release tablets are not directly interchangeable. Changes between them should be made by the healthcare professional.
The appropriate dose depends on the condition, age, body weight, treatment phase, kidney or liver function and interacting medications. Patients should follow the prescription label and should not use another patient’s dosage as guidance.
Online Reviews Are Not Dosing InstructionsRinvoq doses and treatment schedules differ among conditions. A dose used for inflammatory bowel disease may not be the dose used for rheumatoid arthritis, eczema or another condition.
Contact the prescriber or pharmacist about a missed dose, accidental extra dose, tablet residue, medication interaction or treatment interruption.
Rinvoq FDA Boxed Warning Explained
Serious Infections
Rinvoq can reduce the body’s ability to fight infections. Serious and sometimes fatal infections have been reported, including tuberculosis, bacterial infections, fungal infections and viral infections such as shingles.
The prescribing information says patients should be evaluated for active and latent tuberculosis before treatment. Patients should also be monitored for infection during and after treatment.
Mortality
The boxed warning discusses a higher rate of death observed in a safety study involving another JAK inhibitor compared with TNF blockers among rheumatoid-arthritis patients age 50 or older who had at least one cardiovascular risk factor.
Cancer
Lymphoma and other cancers have occurred in patients receiving Rinvoq. The warning notes additional risk considerations for current and former smokers. Healthcare professionals may recommend periodic skin examinations.
Major Cardiovascular Events
The label warns about major cardiovascular events such as heart attack and stroke. Age, smoking history and other cardiovascular risk factors may influence the treatment decision.
Blood Clots
Deep-vein thrombosis, pulmonary embolism and arterial thrombosis have occurred in people receiving JAK inhibitors, including Rinvoq. Some events were serious or fatal.
Symptoms That May Require Urgent Medical CareSeek prompt medical evaluation for symptoms that could indicate a serious infection, blood clot, heart attack, stroke, severe allergic reaction or gastrointestinal perforation.
Possible warning signs include sudden chest or upper-back pain, difficulty breathing, swelling or pain in a leg, sudden weakness on one side, difficulty speaking, facial or throat swelling, persistent fever, severe abdominal pain or sudden vision changes.
Call emergency services when symptoms appear life-threatening. This list is not complete; read the Medication Guide and follow the instructions supplied by the healthcare professional.
Other Rinvoq Warnings and Precautions
The prescribing information also discusses:
- Hypersensitivity reactions, including anaphylaxis and angioedema
- Gastrointestinal perforations
- Low blood sugar in patients with diabetes
- Low neutrophil or lymphocyte counts
- Decreased hemoglobin
- Changes in cholesterol and other lipid measurements
- Elevated liver enzymes
- Potential fetal harm during pregnancy
- Vaccination precautions
- Medication residue appearing in stool or ostomy output
- Retinal detachment reported in atopic-dermatitis clinical trials
The risks and common adverse reactions can vary with the medical condition, dose, treatment phase and other medicines being used.
Commonly Reported Rinvoq Side Effects
Adverse reactions reported in Rinvoq clinical trials include different combinations of the following, depending on the treated condition:
- Upper respiratory infections
- Nausea
- Cough
- Fever
- Headache
- Acne
- Fatigue
- Abdominal pain
- Shingles or other herpes infections
- Increased weight
- Anemia
- Changes in white blood cells
- Increased liver enzymes
- Increased blood creatine phosphokinase
- Rash or folliculitis
This is not a complete side-effect list. A symptom occurring during treatment is not automatically caused by Rinvoq, but it should be discussed with the prescribing healthcare professional.
Testing and Monitoring Before and During Rinvoq
The current prescribing information recommends that healthcare professionals consider several evaluations before treatment:
- Active and latent tuberculosis testing
- Viral hepatitis screening
- A complete blood count
- Baseline liver function
- Pregnancy-status verification when applicable
- Review and updating of immunizations
During treatment, monitoring may include blood counts, liver enzymes, lipid measurements and evaluation for infections or other adverse reactions. The label recommends assessing lipids approximately 12 weeks after treatment begins and thereafter according to applicable clinical guidance.
Live vaccines should generally be avoided during or immediately before Rinvoq treatment. Patients should tell the healthcare professional administering a vaccine that they are taking Rinvoq.
Information To Discuss Before Starting Rinvoq
Patients should tell their healthcare professional about:
- Current, recent, chronic or recurring infections
- Tuberculosis exposure or previous positive testing
- Hepatitis B or hepatitis C
- Cancer or a history of cancer
- Heart attack, stroke or cardiovascular risk factors
- Current or past smoking
- Blood clots or clotting risk factors
- Diverticulitis, ulcers or other gastrointestinal problems
- Kidney or liver problems
- Diabetes and glucose-lowering medications
- Recent or planned vaccinations
- Pregnancy, pregnancy plans or breastfeeding
- Every prescription, nonprescription medicine, vitamin and supplement being used
Rinvoq is not recommended in combination with certain other JAK inhibitors, biologic therapies or potent immunosuppressants. The exact limitation depends on the treated condition.
What Patients Say They Like About Rinvoq
Improved Symptoms
Positive patient reviews sometimes describe reduced joint pain, swelling, stiffness, skin symptoms, itching, bowel urgency, abdominal symptoms or fatigue. The reported benefit depends on the underlying condition.
Improved Daily Function
Some reviewers say symptom improvement helped them return to work, exercise, sleep more comfortably or complete ordinary activities.
Oral Administration
Some patients prefer a tablet to an injection or infusion. This preference does not determine whether Rinvoq is medically appropriate.
Response After Previous Treatments
Positive reviews occasionally come from people who say other medications did not adequately control their condition before Rinvoq was prescribed.
Relatively Fast Improvement for Some Patients
Some reviewers report noticing improvement early in treatment. Others describe a slower response or no meaningful benefit. An individual review cannot predict another patient’s timeline.
Common Rinvoq Complaints
Limited or Inconsistent Effectiveness
Some patients report little improvement, a partial response or benefits that decreased over time. Disease activity can also change independently of treatment.
Suspected Side Effects
Complaints may involve infections, acne, headaches, fatigue, weight changes, gastrointestinal symptoms, laboratory changes or other symptoms believed to be connected with treatment.
Concern About Serious Risks
Some patients are uncomfortable with the boxed warning or with their personal cardiovascular, infection, cancer or clotting risk.
Blood Testing and Monitoring
Reviewers may find recurring laboratory tests, appointments and follow-up inconvenient or stressful. Monitoring is an important part of safe treatment.
Insurance Prior Authorization
Some complaints involve an insurer requiring medical records, proof of previous treatment, repeated authorization or an appeal before covering Rinvoq.
Specialty-Pharmacy Delays
Patients sometimes report difficulty coordinating the prescriber, insurer, manufacturer-support program and specialty pharmacy, leading to refill delays.
Cost and Copay Concerns
Out-of-pocket costs vary widely. A patient with a savings card may have a very different experience from someone with Medicare, Medicaid, another government program or no prescription coverage.
Public Rinvoq Review Snapshot
When checked in September 2026, Zero Stars had no published Rinvoq reviews. The listing’s displayed 0 was based on 0 reviews and should not be interpreted as a neutral rating.
The Rinvoq review page on Drugs.com displayed an average rating of 7.1 out of 10 from 280 reviews. The site reported that 57% described a positive experience and 16% described a negative experience.
The Rinvoq review page on WebMD displayed an average rating of 3.6 out of 5 from 68 reviews.
These are voluntary, self-reported reviews. The patients may have different diagnoses, doses, treatment histories and health risks. The scores should not be averaged or treated as clinical evidence.
Rinvoq Cost and Insurance Complaints
AbbVie’s Rinvoq cost page listed a wholesale acquisition cost of $7,090.41 for a 30-day supply as of January 6, 2026. That list price is not necessarily what an individual patient, insurer or pharmacy pays.
Actual out-of-pocket cost may depend on:
- The insurance plan and formulary
- Deductible and coverage phase
- Prior-authorization requirements
- The prescribed dose and quantity
- The specialty pharmacy used
- Commercial savings-card eligibility
- Manufacturer patient-assistance eligibility
- Medicare, Medicaid or other government coverage
RINVOQ Complete can be reached at 1-800-274-6867 for insurance and potential savings information. Savings programs have eligibility requirements, maximum benefits and exclusions. A savings card is not health insurance and is not available to every patient.
What To Do If Insurance Denies Rinvoq
- Request the denial in writing. Identify the reason, plan provision and appeal deadline.
- Ask which requirement was not met. The plan may require previous medications, medical records or a particular diagnosis.
- Contact the prescriber. The medical office may need to submit clinical notes, treatment history or a medical-necessity statement.
- Confirm the specialty pharmacy. Some plans require prescriptions to be filled through a designated pharmacy.
- Request an appeal. Follow the plan’s procedure and retain the submission confirmation.
- Ask about an expedited review. This may be available when a delay could seriously affect health, subject to plan rules.
- Contact RINVOQ Complete. Ask an Insurance Specialist about coverage verification and available support.
- Preserve every deadline. Waiting for a callback does not necessarily extend an insurer’s appeal period.
How To Report a Rinvoq Side Effect
- Contact the prescribing healthcare professional. Discuss the symptom, when it began, severity and any other medications or illnesses.
- Seek urgent care when appropriate. Do not wait for a manufacturer or FDA response to a medical emergency.
- Report to AbbVie. Call 1-800-633-9110 for a suspected side effect or product-quality concern.
- Consider an FDA report. Patients and healthcare professionals can use FDA MedWatch or call 1-800-332-1088.
- Keep the medication information. Record the product, dose, lot number, start date and pharmacy without publishing those details publicly.
- Document the outcome. Include medical evaluation, treatment, laboratory findings and whether the medicine was continued, interrupted or changed by the healthcare professional.
Submitting an adverse-event report does not prove that Rinvoq caused the event. Reports help regulators and manufacturers monitor potential safety patterns.
How To Report a Rinvoq Product-Quality Problem
A product-quality concern may involve damaged packaging, an unusual tablet appearance, a broken seal, incorrect labeling, storage problems or suspected contamination.
- Do not use a product that appears damaged or incorrect until a pharmacist or healthcare professional advises otherwise.
- Keep the original container and packaging.
- Contact the dispensing pharmacy.
- Call AbbVie at 1-800-633-9110.
- Retain the lot number, expiration date and photographs for private submission.
Rinvoq Compared With Other Treatment Options
Humira, Enbrel, Xeljanz and other immune-modifying medicines should not be treated as interchangeable competitors. They have different mechanisms, indications, administration methods, eligibility requirements and safety considerations.
Depending on the condition, alternatives may include:
- TNF-blocking medications
- Other biologic medications
- Other JAK inhibitors or targeted oral medicines
- Conventional disease-modifying medications
- Corticosteroids for selected situations
- Topical treatments for certain skin conditions
- Condition-specific surgical, nutritional or supportive care
A healthcare professional may consider disease severity, previous treatments, infection history, vaccination status, cancer history, pregnancy, cardiovascular risk, smoking, clotting risk, laboratory findings, insurance coverage and patient preference.
Do not switch, combine or stop immune-modifying medications without instructions from the prescribing healthcare professional.
Frequently Asked Questions About Rinvoq
What is Rinvoq?
Rinvoq is the brand name for upadacitinib, a prescription Janus kinase inhibitor manufactured by AbbVie.
What conditions is Rinvoq approved to treat?
Current U.S. labeling includes rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis and giant cell arteritis. Eligibility requirements differ.
Does Rinvoq have an FDA boxed warning?
Yes. The boxed warning covers serious infections, mortality, malignancies, major cardiovascular events and thrombosis.
Is Rinvoq a biologic?
No. Rinvoq is a targeted oral JAK inhibitor. It affects immune signaling but is not a biologic medication.
Can Rinvoq tablets be crushed or split?
No. The prescribing information says Rinvoq extended-release tablets should be swallowed whole and not split, crushed or chewed.
Can Rinvoq be taken with other immune medications?
The prescribing information does not recommend combining Rinvoq with certain JAK inhibitors, biologic therapies or potent immunosuppressants. Patients should provide their complete medication list to the prescriber and pharmacist.
What is the RINVOQ Complete phone number?
RINVOQ Complete patient support can be reached at 1-800-274-6867.
How do I report a suspected Rinvoq side effect?
Contact the prescribing healthcare professional. Suspected adverse reactions may also be reported to AbbVie at 1-800-633-9110 or through FDA MedWatch.
Does Zero Stars currently have a Rinvoq rating?
No. When this article was updated, the listing had no published reviews. Its displayed 0 therefore represented no rating history.
Can Zero Stars determine whether I should take Rinvoq?
No. Zero Stars cannot diagnose a condition, evaluate personal risks, recommend a dose or determine whether someone should begin or stop a prescription medication.
What To Include in a Rinvoq Review
A useful review may explain:
- The condition being treated, if the reviewer is comfortable sharing it
- The approximate length of treatment
- Whether Rinvoq was a first treatment or followed other therapies
- The symptoms that improved, remained unchanged or worsened
- How long it took to notice a change
- Suspected side effects and whether they were medically evaluated
- Laboratory or monitoring concerns without publishing records
- Insurance, prior-authorization or specialty-pharmacy problems
- Whether manufacturer support was helpful
- Whether the problem was resolved
Protect Your Medical PrivacyDo not upload or publish a prescription label, medical record, laboratory report, insurance card, prior-authorization document or photograph containing a full name, birth date, address, patient number, prescription number or insurance identification number.
Do not post a child’s identifying information. Send private medical and insurance documents only through an authorized healthcare, pharmacy, insurer, manufacturer or government reporting channel.
Related ZeroStars Reviews: Readers researching medications and health products may also be interested in reviews and complaints about Friday Plans, Ro Sparks, and Cognilux. You can also browse additional health product and supplement reviews on ZeroStars.
How To Rate Rinvoq on Zero Stars
Zero Stars uses a color-coded scale from -5 stars to +5 stars. A rating can consider symptom response, side effects, monitoring, cost, insurance, pharmacy service, manufacturer support and the final outcome.
A patient rating describes an individual experience. It is not medical evidence or a treatment recommendation.
Negative Ratings: -1 to -5 Stars
- -5 stars: The worst possible treatment, side-effect or access experience
- -3 to -4 stars: Serious unresolved effectiveness, tolerance, cost or support concerns
- -1 to -2 stars: A disappointing experience with some limited positive aspects
Neutral Rating: 0 Stars
0 stars: A genuinely neutral, average or evenly mixed experience. The site’s automatic display of 0 when no reviews exist is not a patient rating.
Positive Ratings: +1 to +5 Stars
- +1 to +2 stars: More positive than negative despite some concerns
- +3 to +4 stars: A good treatment or support experience
- +5 stars: Exceptional symptom improvement, tolerability and access experience
Share Your Rinvoq ReviewHave you been prescribed Rinvoq? Leave a rating from -5 to +5 stars and describe the condition, treatment duration, results, side effects, insurance experience and final outcome to the extent you are comfortable.
Do not use a public review as a substitute for reporting a serious side effect to a healthcare professional, AbbVie or the FDA.
Conclusion
Rinvoq is an FDA-approved prescription medication used for several inflammatory and autoimmune diseases. Some patients report meaningful symptom relief and improved daily function, while others describe limited effectiveness, side effects, monitoring concerns, high costs or difficulty obtaining insurance approval.
The medication carries an important boxed warning involving serious infections, mortality, cancer, major cardiovascular events and thrombosis. Patients should review these risks and their individual medical history with a qualified healthcare professional.
Online patient reviews can help identify questions to ask, but they cannot determine whether Rinvoq is safe, effective or appropriate for another person.
Comments and Discussions
Join the conversation below. Read Rinvoq reviews, ask general questions and share what happened with treatment, side effects, insurance, a specialty pharmacy or patient support.
Information reviewed and updated September 2026. ZeroStars.org is an independent review platform and is not affiliated with AbbVie Inc. This article provides general consumer information and does not provide medical advice, diagnosis or treatment. Rinvoq indications, warnings, prices and support programs can change. Consult the current prescribing information and a qualified healthcare professional.